MBI (1783) reported revenue of NT$74.4 million for Oct 2026, +17.3% year on year and -15.6% from the previous month. Revenue for Jan–Oct 2026 was NT$706.6 million (+8.7% year on year).
In Oct 2026, it ranked No. 89 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$74.4 million | +17.3% | -15.6% |
| Sep 2026 | NT$88.1 million | +35.3% | +28.5% |
| Aug 2026 | NT$68.5 million | -2.5% | +7.5% |
| Jul 2026 | NT$63.8 million | -2.6% | -26.0% |
| Jun 2026 | NT$86.1 million | +9.2% | +17.0% |
| May 2026 | NT$73.6 million | -4.4% | +20.1% |
| Apr 2026 | NT$61.3 million | +15.8% | -12.4% |
| Mar 2026 | NT$69.9 million | +0.1% | +45.8% |
| Feb 2026 | NT$48 million | +20.9% | -34.3% |
| Jan 2026 | NT$73 million | +7.9% | -21.4% |
| Dec 2025 | NT$92.9 million | +33.1% | +35.8% |
| Nov 2025 | NT$68.4 million | -7.4% | +7.8% |
| Oct 2025 | NT$63.4 million | +2.3% | -2.6% |
| Sep 2025 | NT$65.1 million | +3.3% | -7.3% |
| Aug 2025 | NT$70.3 million | +27.9% | +7.3% |
| Jul 2025 | NT$65.5 million | +17.0% | -17.0% |
| Jun 2025 | NT$78.9 million | +38.5% | +2.4% |
| May 2025 | NT$77 million | +18.5% | +45.6% |
| Apr 2025 | NT$52.9 million | +1.6% | -24.3% |
| Mar 2025 | NT$69.9 million | +81.6% | +76.2% |
| Feb 2025 | NT$39.7 million | +6.1% | -41.3% |
| Jan 2025 | NT$67.6 million | +32.1% | -3.1% |
| Dec 2024 | NT$69.8 million | +47.4% | -5.5% |
| Nov 2024 | NT$73.9 million | +32.8% | +19.2% |
| Oct 2024 | NT$62 million | +35.4% | -1.7% |
Jan–Oct 2026 cumulative: NT$706.6 million (+8.7% YoY)
Other Biotech & Medical companies
Compare with peers: MBI vs PEC / MBI vs Lotus Pharm / MBI vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16